FDA Approves Ozempic To Treat Chronic Kidney Disease

The U.S. Food and Drug Administration (FDA) approved Ozempic® as a treatment to reduce the risk of worsening chronic kidney disease (CKD) among adults with type 2 diabetes (T2D) and CKD. Ozempic (semaglutide) is an injected glucagon-like peptide-1 receptor agonist (GLP-1 RA). It has previously been approved as a treatment for adults with T2D to improve blood sugar control, and to reduce the risk of death from cardiovascular disease among adults with T2D and heart disease. Ozempic is manufactured by Novo Nordisk.

The FDA approval for this new indication based on the results of the FLOW . . .